2型糖尿病与皮肤黑色素瘤侵袭性标志物的关系:443例患者的多中心观察性研究
这项多中心横断面研究纳入443例皮肤黑色素瘤患者,发现2型糖尿病与诊断时更强的侵袭性相关,包括Breslow厚度>2mm和>4mm、肿瘤核分裂率>5/mm²、前哨淋巴结受累及III-IV期。糖化血红蛋白水平和二甲双胍治疗与侵袭性无显著关联。
要点
- 2型糖尿病与黑色素瘤诊断时更强侵袭性独立相关。
- 糖化血红蛋白水平和二甲双胍治疗与侵袭性无显著关联。
- 糖尿病黑色素瘤患者应关注分期和侵袭性评估。
核心结论
- 2型糖尿病而非血糖控制或二甲双胍治疗与诊断时皮肤黑色素瘤侵袭性增加相关。
研究设计与样本
- 多中心横断面研究纳入443例诊断皮肤黑色素瘤患者,采用标准化方案并检测空腹血糖、糖化血红蛋白和系统炎症标志物。
主要发现
- 糖化血红蛋白水平和二甲双胍治疗与黑色素瘤侵袭性无显著关联。
临床怎么用
- 对合并2型糖尿病的皮肤黑色素瘤患者,诊断时应更关注侵袭性指标如Breslow厚度、核分裂率和前哨淋巴结状态。
局限性
- 横断面设计无法推断因果关系。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some studies have suggested a relationship between type 2 diabetes mellitus (T2DM) and increased incidence of melanoma. Efforts are under way to identify preventable and treatable factors associated with greater melanoma aggressiveness, but no studies to date have examined the relationship between T2DM and the aggressiveness of cutaneous melanoma at diagnosis. OBJECTIVES: To explore potential associations between T2DM, glycaemic control and metformin treatment and the aggressiveness of cutaneous melanoma. METHODS: We conducted a cross-sectional multicentric study in 443 patients diagnosed with cutaneous melanoma. At diagnosis, all patients completed a standardized protocol, and a fasting blood sample was extracted to analyse their glucose levels, glycated haemoglobin concentration and markers of systemic inflammation. Melanoma characteristics and aggressiveness factors [Breslow thickness, ulceration, tumour mitotic rate (TMR), sentinel lymph node (SLN) involvement and tumour stage] were also recorded. RESULTS: The mean (SD) age of the patients was 55·98 (15·3) years and 50·6% were male. The median Breslow thickness was 0·85 mm. In total, 48 (10·8%) patients were diagnosed with T2DM and this finding was associated with a Breslow thickness > 2 mm [odds ratio (OR) 2·6, 95% confidence interval (CI) 1·4-4·9; P = 0·004)] and > 4 mm (OR 3·6, 95% CI 1·7-7·9; P = 0·001), TMR > 5 per mm2 (OR 4·5, 95% CI 1·4-13·7; P = 0·009), SLN involvement (OR 2·3, 95% CI 1-5·7; P = 0·038) and tumour stages III-IV (vs. I-II) (OR 3·4, 95% CI 1·6-7·4; P = 0·002), after adjusting for age, sex, obesity, alcohol intake and smoking habits. No significant associations emerged between glycated haemoglobin levels, metformin treatment and melanoma aggressiveness. CONCLUSIONS: T2DM, rather than glycaemic control and metformin treatment, is associated with increased cutaneous melanoma aggressiveness at diagnosis.
引用
- Nagore E, Martinez-Garcia MA, Gomez-Olivas JD, et al. Relationship between type 2 diabetes mellitus and markers of cutaneous melanoma aggressiveness: an observational multicentric study in 443 patients with melanoma. Br J Dermatol. 2021. PMID: 33453061. doi:10.1111/bjd.19813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。